View Item 

Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART

Access Status
Fulltext not available
Authors
Yunihastuti, E.
Lee, S.
Gani, R.
Saraswati, H.
Sundaru, H.
Lesmana, L.
Sukmana, N.
Price, Patricia
Date
2011
Type
Journal Article

Metadata
Show full item record
Citation
Yunihastuti, E. and Lee, S. and Gani, R. and Saraswati, H. and Sundaru, H. and Lesmana, L. and Sukmana, N. et al. 2011. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Clinical Immunology. 139 (1): pp. 32-39.
Source Title
Clinical Immunology
DOI
ISSN
School
School of Biomedical Sciences
URI
Collection
Abstract

Some HIV/hepatitis C virus co-infected patients beginning ART experience Immune Restoration Disease (IRD) manifested as a rise in serum alanine transaminase. This was investigated in HIV/HCV co-infected individuals (n = 50) commencing ART in Jakarta (Indonesia). Samples were collected at weeks 0, 4, 8, 12, 24 and at HCV IRD. Nine patients experienced HCV IRD (incidence = 9.2 per 1000 person-weeks). These resolved without changing treatment. Markers of T-cell activation (sCD26, sCD30) and immune recruitment (CXCL10) increased in many HCV IRD cases, so T-cells may mediate HCV IRD. Total anti-HCV antibody (core, NS3, NS4) remained lower in HCV IRD cases, but levels of antibody to core were not lower in HCV IRD cases. Rises in HCV RNA on ART were independent of HCV IRD, but there was a negative correlation between baseline HCV RNA and total anti-HCV antibody. High levels of antibody may protect against HCV IRD, via lower HCV antigen loads. © 2011 Elsevier Inc.